Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nephrol Dial Transplant ; 33(8): 1362-1372, 2018 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-29186537

RESUMO

Background: Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz Severity Score Index. Methods: In this prospective observational study, we assessed end-organ damage and clinical symptoms in 112 patients who had received agalsidase-beta (1.0 mg/kg) for >1 year, who were (i) non-randomly assigned to continue this treatment regime (regular-dose group, n = 37); (ii) received a reduced dose of agalsidase-beta and subsequent switch to agalsidase-alfa (0.2 mg/kg) or a direct switch to 0.2 mg/kg agalsidase-alfa (switch group, n = 38); or (iii) were re-switched to agalsidase-beta after receiving agalsidase-alfa for at least 12 months (re-switch group, n = 37) with a median follow-up of 53 (38-57) months. Results: eGFR of patients in the regular-dose group remained stable. Patients in the switch group showed an annual eGFR loss of - 4.6 ± 9.1 mL/min/1.73 m2 (P < 0.05). Patients in the re-switch group also had an eGFR loss of - 2.2 ± 4.4 mL/min/1.73 m2 after re-switch to agalsidase-beta, but to a lower degree compared with the switch group (P < 0.05). Patients in the re-switch group suffered less frequently from diarrhoea (relative risk 0.42; 95% confidence interval 0.19-0.93; P = 0.02). Lyso-Gb3 remained stable in the switch (P = 0.97) and the regular-dose (P = 0.48) groups, but decreased in the re-switch group after change of the therapy regimen (P < 0.05). Conclusions: After switch to agalsidase-alfa, Fabry patients experienced a continuous decline in eGFR, while this decline was attenuated in patients who were re-switched to agalsidase-beta. Decreasing lyso-Gb3 levels may indicate a better treatment response in the latter group.


Assuntos
Terapia de Reposição de Enzimas/métodos , Doença de Fabry/tratamento farmacológico , Isoenzimas/uso terapêutico , alfa-Galactosidase/uso terapêutico , Adulto , Idoso , Relação Dose-Resposta a Droga , Doença de Fabry/enzimologia , Feminino , Taxa de Filtração Glomerular , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento
2.
Herzschrittmacherther Elektrophysiol ; 33(3): 334-337, 2022 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-35781831

RESUMO

We present a rare reversible cause of bradycardia. A 49-year-old man who suffered from syncope was administered to our emergency department. In preclinical ECG recordings, a sinus node arrest was documented. All following examinations documented normal sinus node function. Finally, grayanotoxin poisoning, which can be present in honey from the Black Sea region, was proven. A pacemaker implantation could be avoided in this reversible cause of bradyarrhythmia.


Assuntos
Mel , Rhododendron , Bradicardia/diagnóstico , Bradicardia/etiologia , Bradicardia/terapia , Eletrocardiografia , Humanos , Masculino , Pessoa de Meia-Idade , Síncope/diagnóstico , Síncope/etiologia , Paladar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA